GH Research PLC Ordinary Shares (GHRS) Dividend History

Company News

• GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

  GH Research PLC reported positive results from a Phase 2b trial of its lead product candidate GH001 in patients with treatment-resistant depression, meeting the primary endpoint with a significant placebo-adjusted reduction in depression scores. The company also provided updates on its financial position and ongoing clinical development activities.

  GlobeNewswire Inc.
• Postpartum Depression Pipeline Revealed in 2025 Forecast Report Featuring GH Research, Reunion Neuroscience, Lipocine, and Brii Biosciences

  The report provides an in-depth analysis of the Postpartum Depression (PPD) pipeline, showcasing insights into more than ten diverse companies and over ten pipeline drugs. It highlights innovative therapeutic candidates, including RE-104 by Reunion Neuroscience and GH001 by GH Research, and their potential impact on PPD treatment paradigms.

  GlobeNewswire Inc.

  Featured Companies: LPCN
• GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

  GH Research PLC reported positive results from its Phase 2b clinical trial of GH001 in patients with treatment-resistant depression, with the primary endpoint met and a majority of patients achieving remission. The company also provided updates on its Phase 1 trial for a proprietary aerosol delivery device and its response to the IND hold on GH001. The company's cash position remains strong, with additional funding received from a public offering.

  GlobeNewswire Inc.
• Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight

  The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.

  GlobeNewswire Inc.

  Featured Companies: ATAI AXSM JNJ LPCN RLMD SAGE
• GH Research Announces Pricing of $150 Million Public Offering

  GH Research PLC, a clinical-stage biopharmaceutical company, announced the pricing of its $150 million public offering of 10,000,000 ordinary shares at $15.00 per share. The company is developing a novel treatment for treatment-resistant depression.

  GlobeNewswire Inc.